On the stock market since 2021, it operates in the world of health and science. It has 52 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 39% a year over the last 4 years. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 21% a year on average.
Sales run at $382K a year. A small number, but proof the product has real buyers.
There is $1.3M in the vault; even if every debt were paid off, $783K would remain.
A loss of $0 against $382K in annual sales.
The stock sits at $0.12. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, VBIO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VBIO is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.